IbSium® efficacy in supporting digestive health, discover our latest clinical validation

Share this article:

Digestive health remains the market-leading benefit targeted by probiotics and the number one reason for consumers to buy nutraceuticals. Over the past 20 years, an increasing amount of evidence on probiotics efficacy has reinforced probiotics awareness and lead to millions of people taking probiotics for their digestive health.

Last January, a new published independent clinical study confirmed the efficacy of our “gut-friendly” probiotic yeast Saccharomyces cerevisiae CNCM I-3856 (marketed as ibSium®) to support digestive health.

Indeed, this study confirms the beneficial effects of this proprietary strain for abdominal pain management and bowel habits improvements in the general IBS population.

With this clinical study, ibSium® confirms its positioning as one of the most documented probiotics to support intestinal comfort.

If you wish to receive a copy to introduce ibSium® benefits to your customers, please fill in the contact form and ask for it!

101 rue de Menin
59700 Marcq-en-Baroeul

Subscribe to our newsletter

The latest news, articles, and resources, sent to your inbox twice a month. 

The information provided here is, to the best of our knowledge, true and accurate. However, our products must only be used in compliance with local laws and regulations. We cannot guarantee the freedom of use for every intended application or country. These statements may not have been evaluated by your local Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. A healthy, balanced and diversified diet should fulfill all nutritional needs.